Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T27791 |
Ladarixin Sodium
DF 2156A,DF-2156,DF2156A,DF2156,DF 2156,DF-2156A |
||
Ladarixin Sodium, an Chemokine CXCR antagonist, is used potentially for the treatment of type I diabetes. | |||
T32533 |
Ladarixin
DF 2156A,DF2156A,DF-2156,DF 2156,DF-2156A,DF2156 |
||
Ladarixin is a dual, non-competitive allosteric inhibitor of CXCR1 and CXCR2 interleukin8 (IL-8a and IL-8b, respectively). The efficacy of CXCR1/2 inhibition prevents inflammation and autoimmune-mediated islet damage. |